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Abstract: Nutrition is involved in several aspects of pediatric inflammatory bowel disease (IBD),
ranging from disease etiology to induction and maintenance of disease. With regards to etiology,
there are pediatric data, mainly from case-control studies, which suggest that some dietary habits
(for example consumption of animal protein, fatty foods, high sugar intake) may predispose patients
to IBD onset. As for disease treatment, exclusive enteral nutrition (EEN) is an extensively studied,
well established, and valid approach to the remission of pediatric Crohn’s disease (CD). Apart from
EEN, several new nutritional approaches are emerging and have proved to be successful (specific
carbohydrate diet and CD exclusion diet) but the available evidence is not strong enough to
recommend this kind of intervention in clinical practice and new large experimental controlled
studies are needed, especially in the pediatric population. Moreover, efforts are being made to
identify foods with anti-inflammatory properties such as curcumin and long-chain polyunsaturated
fatty acids n-3, which can possibly be effective in maintenance of disease. The present systematic
review aims at reviewing the scientific literature on all aspects of nutrition in pediatric IBD, including
the most recent advances on nutritional therapy.
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1. Introduction
Nutrition is involved in several aspects of pediatric inflammatory bowel disease (IBD), ranging
from disease etiology to induction and maintenance of disease. The etiology of inflammatory bowel
disease (IBD) is believed to be multifactorial, caused by an interplay of genetic, environmental,
microbial, and immunological factors. Among the environmental risk factors, dietary elements have
received considerable attention in recent years. Epidemiological studies have demonstrated a rising
incidence of IBD in countries where the disease is more prevalent, such as Europe and North America,
as well as in areas where IBD was previously thought to be uncommon [1]. This increase has occurred
with the spread of the “Western” diet, which is high in fat and protein but low in fruit and vegetables [2,3].
Numerous studies, conducted mainly in adults, assessed whether there are associations between
the development of IBD and diet and suggested that specific nutrients may play a role as risk
factors or protective factors for the development of disease [3–8]. However, it must be noted that
many of these studies rely on food frequency questionnaires, which have a poor accuracy due
to recall bias. The hypothesis of dietary factors influencing gut inflammation may be explained
through several biological mechanisms, including antigen presentation, change in prostaglandin
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balance, and alteration of the microflora [2,9]. Aside from etiology, nutrition plays a significant role
in treatment of disease. Among the traditional nutritional approaches, exclusive enteral nutrition
(EEN) is an extensively studied, well established, and valid approach to remission of pediatric
Crohn’s disease (CD). The latter nutritional therapy presents several advantages including control of
inflammatory changes, mucosal healing, positive benefits to growth and overall nutritional status, and
avoidance of other medical therapies. Aside from EEN, recently several new nutritional approaches
are emerging and have seemed to be successful. The present systematic review aims at reviewing the
scientific literature on all aspects of nutrition in pediatric IBD, including the most recent advances in
nutritional therapy.
2. Methods
A structured literature search was performed by two investigators (Francesca Penagini and
Barbara Borsani) independently, in PubMed, EMBASE, and Medline starting from January 1982 up
to April 2016 using the following keywords: “Pediatric Inflammatory Bowel Disease”, “Pediatric IBD”,
“Inflammatory Bowel Disease in children”, “IBD in children” in any combination with “diet”, “dietary
intakes”, “nutrition” and cross referenced with “etiology”, “induction of remission”, “relapse” and
“treatment”. The search was limited to full-text papers in English and resulted in a total of 8229 articles.
By screening titles and abstracts, studies performed in vitro, in animals, uncontrolled studies, case reports,
and reviews were excluded. Duplicate studies were removed. Eligible papers were cross-checked for
references, which resulted in two additional papers. Figure 1 shows the flow-chart of our systematic
review. For randomized clinical trials the absolute risk change with exact 95% confidence intervals (CI)
was calculated. For cohort studies, the incidence rates with exact 95% CI were calculated.
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3. Nutrition in Etiology of Pediatric Inflammatory Bowel Disease
Data on diet as a risk factor for the onset of pediatric IBD are scarce. There are few studies in the
literature apart from case-control studies, which have shown a potential role of some dietary elements
as risk factors for disease onset in pediatric IBD. Nevertheless, these studies present methodological
limitations such as the use of self-administered patient questionnaires, therefore recall bias. Table 1
summarizes the main studies on nutrition factors in etiology of pediatric IBD.
The Japanese Epidemiology Group of the Research Committee of IBD conducted a multisite,
hospital-based, case-control study to examine the environmental risk factors for UC in 101 patients who
were 10–39 years old at the time of disease onset [10]. Information was obtained from self-administered
patient questionnaires. Combined consumption of Western foods (bread for breakfast, butter,
margarine, cheese, meats, and ham and sausage) was significantly related to an increased risk of
UC Relative risk (RR) for low consumption of Western foods 1.0 (CI not available), for intermediate
consumption RR = 1.9; 95% CI 1.0 to 3.7, for high consumption RR = 2.1; 95% CI 1.0 to 4.1, p = 0.04.
Margarine (as an individual Western food item) was positively associated with UC (RR for low
consumption: 1.0 (CI not available), for intermediate consumption RR = 1.2; 95% CI 0.6 to 2.4, for
high consumption RR = 2.6; 95% CI 1.4 to 5.2; trend, p = 0.005. There was also a tendency towards
positive association of bread for breakfast with UC. For low consumption RR = 1.0, for intermediate
consumption RR = 0.7; 95% CI 0.4 to 1.4, for high consumption RR = 2.1; 95% CI 1.0 to 4.3, p = 0.07.
The‘risk did not measurably vary with the consumption of typical Japanese foods, vegetables and
fruits, confectioneries, or soft drinks (RR data not available) [10].
The group of Amre et al. [11] conducted a case-control study evaluating the pre-illness diet
of new onset CD in Canadian children (age < 20 years, n = 103) using a validated food-frequency
questionnaire (FFQ) in comparison to healthy controls matched for age and gender (n = 202). The FFQ
was administered to the cases within one month of diagnosis and investigated dietary habits within
the 12 months prior to disease diagnosis. Results showed negative associations with vegetables
(OR = 0.69; 95% CI 0.33 to1.44, p = 0.03), fruits (OR = 0.49; 95% CI 0.25 to 0.96, p = 0.02), dietary fiber
(OR = 0.12; 95%, CI 0.04 to 0.37, p < 0.001), and fish (OR 0,46, 95% CI 0.20–1.06, p = 0.02); consumption
of long-chain ω-3 fatty acids was negatively associated with CD (OR = 0.44; 95%, CI 0.19 to 1.00,
p < 0.001), whereas positive associations were evident for total fats (OR = 2.30; 95% CI 0.67 to 7.96,
p = 0.15), monounsaturated (OR = 2.41; 95% CI 0.72 to 8.07, p = 0.08), and saturated (OR = 1.81; 95% CI
0.59 to 5.61, p = 0.40) fats, even though these associations were not statistically significant. The authors
concluded that children who consumed higher amounts of fruits were at lower risk for CD (p = 0.02),
as well as children who consumed higher amounts of fish and nuts, rich in long-chainω-3 fatty acids
such as docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA)
(OR = 0.44; 95% CI 0.19 to 1.0, p = 0.03). When the ratio of long chain ω-3/arachidonic acid was
evaluated, a higher ratio was associated with a significantly reduced risk for CD (OR = 0.32; 95% CI
0.14 to 0.71, p = 0.02) [11]. In a similar case-control study, D’Souza et al. [12] investigated the role
of specific dietary patterns in the risk for developing pediatric CD (n = 149, mean age at diagnosis
13.3 ˘ 2.6 years). They observed that dietary patterns characterized by meats, fatty foods, and desserts
were positively associated with pediatric CD in both genders (OR = 4.7, 95% CI 1.6–14.2); on the
contrary, dietary patterns characterized by vegetables, fruits, olive oil, fish, grains, and nuts were
inversely associated with CD in both genders (girls OR = 0.3; 95% CI 0.1 to 0.9; boys OR = 0.2; 95% CI
0.1 to 0.5).
More recently, Jacobsen et al. [13] have investigated environmental risk factors for onset of IBD in
children. The authors included 118 IBD patients aged < 15 years and 447 healthy controls. Risk factors
were investigated by means of a questionnaire. Results showed that a high sugar intake was a risk
factor for IBD (IBD OR = 2.5; 95% CI 1.0 to 6.2, CD OR = 2.9; 95% CI 1.0 to 8.5); while protective factors
were daily vegetable consumption (CD OR = 0.3; 95% CI 0.1 to 1.0), UC OR = 0.3; 95% CI 0.1 to 0.8)
and wholemeal bread consumption (IBD OR = 0.5; 95% CI 0.9 to 0.9), CD OR = 0.4; 95% 0.2 to 0.9) [13].
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Table 1. Dietary factors and etiology in pediatric IBD. IBD = inflammatory bowel disease, UC = ulcerative colitis, CD = Crohn’s disease, LC = long chain.
Dietary Factors and Etiology in Pediatric IBD
Author/Year Study Type Population Main Findings
Gilat et al. 1987 [14] Case-control study
Patients with IBD (n = 499; UC = 197,
CD = 302) aged < 25 years with
disease onset before 20 years of age.
For each patient two age and sex
matched health controls.
- Patients with CD and UC consumed significantly lower fruits and vegetables than
controls (p < 0.01). For UC: low consumption (0 and <1/day) vs. high consumption
(1–3 and >4/day) OR = 0.77; 95% CI 0.45 to 1.35. For CD: low consumption (0 and
<1/day) vs. high consumption (1–3 and >4/day) OR = 0.58; 95% CI 0.37 to 0.91.
- No significant differences were found between patients and controls in the frequency
of breast feeding (p < 0.01), cereal consumption (p < 0.01) and sugar added to milk in
infancy (p < 0.01).
Japanese Epidemiology Group
of the Research Committee of
IBD, 1994 [10]
Case-control study
Patients with UC (n = 101) who were
aged 10–39 years at the time of
disease onset. Healthy control
subjects (n = 143).
- Combined consumption of Western foods (bread for breakfast, butter, margarine,
cheese, meats, and ham and sausage) was significantly related to an increased risk of
UC (Relative risk (RR) for low consumption 1.0, RR for intermediate consumption 1.9;
95% CI 1.0 to 3.7, RR for high consumption 2.1, 95% CI 1.0 to 4.1; trend, p = 0.04).
- Margarine (as an individual Western food item) was positively associated with UC
(trend, p = 0.005).
Baron et al. 2005 [15] Case-control study
IBD patients (n = 282; CD 222, UC 60)
with onset before 17 years of age and
healthy controls matched for age, sex,
and geographical location (n = 282).
- Breastfeeding either partially or exclusively was a risk factor for CD (CD OR = 2.1;
95% CI 1.3 to 3.4, p = 0.003).
- Regular drinking of tap water was a protective factor for CD (CD = OR 0.6; 95% CI
0.3 to 1, p = 0.05).
Amre et al. 2007 [11] Case-control study
Children and adolescents ď20 years
(n = 130), newly diagnosed with CD
mean age at diagnosis (˘SD)
14.2 ˘ 2.7 years. Healthy controls
matched for age and sex (n = 202).
- Higher amounts of vegetables (OR = 0.69; 95% CI 0.33 to 1.44, p = 0.03), fruits
(OR = 0.49; 95% CI 0.25–0.96, p = 0.02), fish (OR = 0.46; 95% CI 0.20 to 1.06, p = 0.02)
and dietary fiber (OR = 0.12; 95%, CI 0.04 to 0.37, p < 0.001) protected from CD.
- Consumption of LCω-3 (OR = 0.44; 95%, CI 0.19 to 1.00, p < 0.001) were negatively
associated with CD.
- A higher ratio of LCω-3/ω-6 fatty acids (OR = 0.32, 95% CI 0.14 to 0.71, p = 0.02)
were significantly associated with lower risks for CD.
D’Souza et al. 2008 [12] Case-control study
Children and adolescents ď20 years
(n = 149), newly diagnosed with CD
mean age at diagnosis (˘SD)
13.3 ˘ 2.6 years. Healthy controls
matched for age and sex (n = 251).
- Meats, fatty foods and desserts (OR = 4.7; 95% CI 1.6 to 14.2) were positively
associated with CD.
- Vegetables, fruits, olive oil, fish, grains, and nuts were inversely associated with CD
in both genders (girls: OR = 0.3; 95% CI 0.1 to 0.9; boys: OR = 0.2; 95% CI 0.1 to 0.5).
Jakobsen et al. 2012 [13] Case-control study
Children and adolescents with IBD
(n = 118; CD 59, UC 56,
IBD-unclassified 3) aged <15 years.
Healthy controls matched for age
and sex (n = 477).
- High sugar intakes were a risk factor for IBD (IBD OR = 2.5; 95% CI 1.0 to 6.2, CD
OR = 2.9; 95% CI 1.0 to 8.5).
- Protective factors were daily vs. less than daily vegetable consumption (CD OR = 0.3;
95% CI 0.1 to 1.0, UC OR = 0.3; 95% CI 0.1 to 0.8) and whole-meal bread consumption
(IBD OR = 0.5; 95% CI 0.3 to 0.9, CD OR = 0.4; 95% CI 0.2 to 0.9).
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There are plausible biological mechanisms that can explain the abovementioned role of dietary
factors in IBD pathogenesis. The n-3 polyunsaturated fatty acids (PUFAs) are present mainly in
fish and can be synthesized in humans from alpha-linolenic acid, an essential fatty acid. EPA is
a constituent of cell membranes and is metabolized to prostaglandin E3 and leukotriene B5, both
of which are less pro-inflammatory than eicosanoids derived from n-6 PUFAs. A diet high in EPA
may therefore protect the colonic mucosa against inflammation [7]. Plausible mechanisms exist
to support the association between fiber intake and risk of CD. Anaerobic bacterial fermentation
of undigested dietary carbohydrates and fiber polysaccharides produces short-chain fatty acids
(SCAFs) like acetate, propionate, and butyrate, which are involved in the maintenance of colonic
homeostasis. These molecules are utilized as fuel sources for colonocyte metabolism and seem to have
an anti-inflammatory effect on epithelial cells, through inhibition of the production and release of
inflammatory mediators. Consequently, a diet poor in fiber and lower in SCFAs may cause a disruption
of the homeostasis between bacteria and colonocytes, leading to intestinal inflammation [16].
4. Nutrition in Induction of Remission in Pediatric Inflammatory Bowel Disease
The first reports on the successful use of enteral nutrition in induction of remission in pediatric CD
date back to the 1980s [17,18]. Since then, exclusive enteral nutrition (EEN) with specific formulas has
been thoroughly studied and has become a well-established nutritional approach shown to alleviate
clinical symptoms, induce mucosal healing, improve nutritional status, and normalize laboratory
parameters associated with active inflammation in pediatric CD. These data have been confirmed
in two meta-analyses demonstrating that EEN is as effective as corticosteroids in inducing disease
remission in pediatric CD [19,20], achieving normalization of inflammatory markers and clinical
remission rates in >80% of subjects [21] irrespective of disease phenotype [22].
Studies on the efficacy of EEN in active CD are reported in Table 2, a comparison between
two different nutritional regimens is given in Table 3, and studies comparing the efficacy of EEN
on corticosteroids in active CD are reported in Table 4. As the included studies were significantly
heterogeneous for study design, outcomes observed, and sample size, a meta-analysis was not performed.
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Table 2. Clinical studies on efficacy of exclusive enteral nutrition in pediatric CD. CREN = constant rate enteral nutrition, PF = polymeric formula, ED = elemental diet,
PCDAI = Pediatric Crohn Disease Activity Index, PEN = partial enteral nutrition, EEN = exclusive enteral nutrition, IFX = infliximab, anti-TNF = anti-tumor necrosis
factor, TGFβ2 = transforming growth factor beta 2.
Clinical Studies on Efficacy of Exclusive Enteral Nutrition
Author/Year Study Type Population Method Main Findings
Navarro et al.
1982 [17] Clinical trial Children with active CD (n = 17)
Exclusive constant rate enteral
nutrition (CREN) using
a combination of elemental diet and
continuous alimentation for
2–7 months, subsequently CREN
used to supplement oral
alimentation from 12 to 22 months.
After 7 months of exclusive CREN: all children’s symptoms
improved; 100% of children presented moderate disease
(Lloyd Still and Green scoring >50).
Fell et al.
2000 [23] Clinical trial Children with active CD (n = 29)
EEN with TGFβ2 enriched PF for
8 weeks.
- After 8 weeks 79% (23/29) of children were in
clinical remission.
- PCDAI declined with treatment. Median PCDAI at baseline
30 (range 12.5–72.5) declined with treatment by a median of
15 at 2 weeks and 25 at 8 weeks (p < 0.00001).
- Macroscopic and histological healing in the terminal ileum
and colon was associated with a decline in ileal and colonic
interleukin-1β. (pre-treatment to post-treatment ratio 0.008
and 0.06: p = 0.001, p = 0.006).
Afzal et al.
2004 [24] Clinical trial
Children and adolescents with
active CD (n = 26), mean age
14 years
EEN with PF for 8 weeks. 88.6% achieved clinical remission.
Bannerjee et
al. 2004 [25] Clinical trial Children with active CD (n = 12) EEN with PF for 6 weeks.
Significant improvements in inflammatory markers by day 3
(p < 0.05) and in clinical activity index PCDAI by day 7.
Gavin et al.
2005 [26]
Retrospective
cohort study
Children and adolescents with
new onset CD (n = 40), aged
6–16 years
EEN with PF for 8 weeks. All patients improved symptomatically and gained weightafter 8 weeks of EEN.
Afzal et al.
2005 [27]
Prospective
cohort study
Children and adolescents with
active CD (n = 65), aged
8–17 years.
Disease localization: ileal
(n = 12), ileocolonic (n = 39),
colonic (n = 14).
EEN with PF for 8 weeks.
77% remission rate. Remission rates: Colonic group: 50%
(7/14), ileocolon group 82.1% (32/39), ileum group 91.7%
(11/12), (χ2 test, p = 0.021)). The colonic disease group
showed the least fall in PCDAI scores at completion of
treatment with EEN (p = 0.03), with the lowest remission
rate (50%).
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Table 2. Cont.
Clinical Studies on Efficacy of Exclusive Enteral Nutrition
Author/Year Study Type Population Method Main Findings
Knight et al.
2005 [28]
Retrospective
cohort study Children with CD (n = 44)
Treatment with EEN as primary
treatment for 6–8 weeks.
90% (40/44) of patients responded to EEN with a median
time to remission of 6 weeks. Crohn’s disease activity index
(CDAI) decreased from pre-EEN to post-EEN, mean values of
CDAI not available.
Day et al.
2006 [29]
Retrospective
cohort study
Children with newly diagnosed
CD (group 1, n = 15) and with
active known long-standing CD
(group 2, n = 12), mean age
11.8 years
- Group 1: EEN with PF for
6–8 weeks as sole initial therapy
- Group 2: EEN with PF for
6–8 weeks in addition to any
current medical therapy.
Twenty-four (89%) of 27 children completed their prescribed
course of EEN. Nineteen (79%) of 24 children entered clinical
remission (80% (12/15) in group 1 and 58% (7/12) in group 2).
There was no clear relationship between disease location and
response to treatment: 75% (3/4) with isolated small bowel,
72.5% (10/14) with ileocolonic and 67% (6/9) with pancolic
disease attained remission (p > 0.05). In group 1 successful
response to EEN was associated with positive weight gains
(average weight gain 4.7 ˘ 3.5 kg) with mean PCDAI
decreasing from 37.1 ˘ 10.8 to 6.7 ˘ 5.1 after 8 weeks
(p < 0.0001). Also in group 2, despite a minor rate of
remission, the overall average PCDAI scores significantly fell
at 8 weeks (p < 0.0001) with an improvement of body weight
and in at least one markers of inflammation.
De Bie et al.
2013 [30]
Retrospective
cohort study
Children with newly diagnosed
CD (n = 77), median age
13.9 years
Patients received EEN (as either
hyperosmolar sip feeds or PF by
nasogastric tube) for 6 weeks as
remission induction therapy,
combined with azathioprine
maintenance treatment in 92%.
In patients completing a 6-week course of EEN (58) complete
remission was achieved in 71% of patients, partial remission
in 26%, and no response in 3%. Complete remission rates
were higher in children presenting with isolated
ileal/ileocaecal disease and malnutrition.
Grover et al.
2016 [31] Clinical trial
Children with newly diagnosed
predominantly luminal CD
(n = 54), median age 12.4 years
EEN for 6–8 weeks in association
with early thiopurine treatment
(<3 months from diagnosis).
Median duration between pre and
post EEN assessments was
60.5 days (IQR 56–69.5)
Post EEN: remission rate (PCDAI < 10) 83% (45/54),
biochemical remission (CRP < 5 mg/dL) 72% (39/54),
complete mucosal healing 33% (18/54). Sustained remission
was superior in those with complete mucosal healing vs.
endoscopic disease 72% (13/18) vs. 28% (10/36), p = 0.003 at
1 year, 50% (8/16) vs. 8% (3/24), p = 0.008 at 2 years and 50%
(8/16) vs. 6% (1/19), p = 0.005 at 3 years.
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Table 3. Clinical studies comparing efficacy between two enteral nutrition regimens. PCDAI = Pediatric Crohn’s Disease Activity Index, PF = polymeric formula,
ED = elemental diet, PEN = partial enteral nutrition, EEN = exclusive enteral nutrition, IFX = infliximab, anti-TNF = anti-tumor necrosis factor, TGFβ2 = transforming
growth factor beta 2, ARC = absolute risk change.
Clinical Studies Comparing Efficacy between Two Enteral Nutrition Regimens
Author/Year Study Type Population Method Main Findings
Akobeng et al.
2000 [32]
Randomized
controlled trial
Children with active CD
(n = 18).
Standard PF with a low glutamine
content (4% of amino-acid composition,
group S) vs. glutamine enriched PF (42%
of amino acid composition, group G) for
4 weeks.
- No difference in remission rates at week 4 between the two groups’
remission 5/9 (55.5%) in group S, 4/9 (44.4%) in group G (p = 0.5).
ARC ´0.11 (exact 95% CI: ´0.57 to 0.35).
- Improvement in mean PCDAI was significantly more in group S
(p = 0.002).
Ludvigsson et al.
2004 [33]
Randomized
controlled trial
Children with active CD
(n = 33) involving small
bowel, colon and
perianal region.
Exclusive EEN with ED (n = 16) vs. PF
(n = 17) for 6 weeks.
- Similar remission rates at 6 weeks (ED 11/16 (69%), PF 14/17 (82%);
p = 0.438). Patients on PF gained more weight compared to ED
(p = 0.004). ARC 0.14 (exact 95% CI: ´0.15 to 0.42).
Johnson et al.
2006 [34]
Randomized
controlled trial
Children with active CD
(n = 50) involving small
bowel and/or colon.
Patients randomly assigned to receive:
- 50% total energy requirements with ED
(PEN, n = 26) for 6 weeks.
- 100% energy requirements with ED
(EEN, n = 24) for 6 weeks.
Remission rate with PEN was lower than with EEN (PEN 4/26 (15%),
EEN 10/24 (42%) p = 0.035). Although PCDAI fell in both groups, the
reduction was greater with EEN (PCDAI reduction PEN ´13, 95% CI
(´7 to ´19) p = 0.001; EEN ´26 95% CI (´19 to ´33), p = 0.001)
(p = 0.005). ARC = ´0.26 (exact 95% CI ´0.50 to ´0.02).
Rodrigues et al.
2007 [35]
Retrospective
cohort study
Children with active CD
(n = 98) involving small
bowel and/or colon.
Children received EEN at the time of first
presentation either PF (n = 45, median
age 12.2 years) or ED (n = 53, median age
11.8 years).
Remission rates were similar between children receiving PF and ED
(ED 64%, 95% CI 51–77 vs. PF 51%, 95% CI 37–66, p = 0.19).
ARC = ´0.13 (exact 95% CI ´0.32 to 0.06).
The use of PF did not affect adherence to EEN but was significantly
associated with reduced need for nasogastric tube administration.
Hartman et al.
2008 [36]
Retrospective
cohort study
Children with CD
(n = 64) involving small
bowel, colon and upper
GI tract.
Group 1 (n = 28, median age 14 years)
and group 2 (n = 18, median age 12.7
years) received TGFβ2-enriched PF vs.
standard PF, respectively, as a
supplement to their regular nutrition
(35%–50% of total caloric intake), for
a median follow-up of 5.3 months for
group 1 and 4.5 months for group 2.
Group 3 (n = 18, median age 12.8 years)
without formula supplementation, for
a median follow-up of 5.5 months.
Supplementation of the diet with PF (both TGFβ enriched and
standard) was associated with a decrease in PCDAI (in group 1 from
34.3 to 15.7, p < 0.0001; in group 2 from 35 to 22, p = 0.02).
No significant decrease in PCDAI was recorded in group 3.
Remission rates at follow-up: 57% (16/28, p = 0.001) in
TGFβ2-enriched PF group, 22.2% (4/18, p = 0.03) in standard PF
group. Remission rate in group 3 was 22.2 (4/18, p = 0.03).
ARC = 0.35 (exact 95% CI 0.08 to 0.61). Significant improvements in
body mass index (p = 0.01) and erythrocyte sedimentation rate
(p = 0.03) were recorded at follow-up (median 3.4 months) only in the
TGFβ2-enriched PF group.
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Table 3. Cont.
Clinical Studies Comparing Efficacy between Two Enteral Nutrition Regimens
Author/Year Study Type Population Method Main Findings
Rubio et al. 2011
[37]
Retrospective
cohort study
Children with newly
diagnosed CD or with
a first relapse of
an established disease
on stable medical
treatment (n = 106).
Children received EEN with PF for
8 weeks as remission induction therapy
either per os (group 1, n = 45, mean age
11.3 years) or by continuous enteral route
via a nasogastric tube (group 2, n = 61,
mean age 10.9 years).
Fractionated oral nutritional therapy (group 1) didn’t significantly
differ from continuous enteral administration (group 2) in inducing
remission (75% vs. 85%, respectively, p = 0.157). All patients showed
a significant decrease in disease severity assessed by PCDAI
(p < 0.0001) and significant improvements in anthropometric
measures and inflammatory indices.
Grogan et al.
2012 [38]
Double-blind
randomized
controlled trial
Children with newly
diagnosed CD (n = 34).
Children were randomized to ED (n = 15,
mean age 12.6 years) or PF (n = 19, mean
age 11.7 years) for 6 weeks and were
followed up for 2 years.
No significant difference was recorded between ED and PF in
inducing remission (93% 14/15 vs. 79% 15/19, respectively).
ARC = 0.14 (exact 95% CI ´0.08 to 0.37). One-third of children
maintained remission at 2 years.
Lee et al. 2015
[39]
Prospective
study
Children with active CD
(n = 90).
Children were treated with anti-TNF
(n = 52), with EEN (n = 22), and with
PEN plus ad lib diet (n = 16) for 8 weeks.
Clinical remission (final PCDAI ď 10) was achieved by 50% on PEN,
76% EEN, and 73% anti-TNF (p = 0.08). ARC= ´0.15 (exact 95% CI
´0.47 to ´0.16). Mucosal healing (estimated by fecal calprotectin
ď 250 µg/g) was achieved with PEN in 14%, EEN 45%, and anti-TNF
62% (p = 0.001). ARC = ´0.25 (exact 95% CI ´0.52 to 0.02).
Table 4. Clinical studies comparing exclusive enteral nutrition to corticosteroids. PCDAI = Pediatric Crohn’s Disease Activity Index, ED = elemental diet,
PEN = partial enteral nutrition, CS = corticosteroids, EEN = exclusive enteral nutrition, IFX = infliximab, anti-TNF = anti-tumor necrosis factor, TGFβ2 = transforming
growth factor beta 2, ARC = absolute risk change.
Clinical Studies Comparing Exclusive Enteral Nutrition to Corticosteroids
Author/Year Study Type Population Method Main Findings
Sanderson et al.
1987 [18]
Randomized
controlled trial
Children and adolescents with active CD
aged 8.6–17.2 years (n = 17) involving the
small bowel.
- 8 children treated with CS
- 9 children treated with exclusive
ED via nasogastric tube
- Disease activity (Lloyd–Still activity index) of the
children improved significantly in both ED and PF
groups after 6 weeks (p < 0.01). Growth velocity
improved more in the ED group
Thomas et al.
1993 [40]
Randomized
controlled trial
Children with active CD (n = 24):
- 8% (2/24) confined to the small bowel
- 29% (7/24) had ileal ˘ caecal involvement
- 25% (6/24) ileocolic disease
- 38% (9/24) disease confined to the colon
Children randomized to receive
ED (n = 12) or CS (n = 12) for
4 weeks.
- Similar improvement in disease activity (PCDAI)
and remission duration in both groups regardless of
site of disease. In CS group activity index at baseline:
74, at week 4: 85, median change +11, (p < 0.01); in ED
group activity index at baseline: 77, at week 4: 88,
median change +11 (p < 0.01).
- Growth velocity significantly better in ED group
compared to CS group.
Nutrients 2016, 8, 334 10 of 27
Table 4. Cont.
Clinical Studies Comparing Exclusive Enteral Nutrition to Corticosteroids
Author/Year Study Type Population Method Main Findings
Ruuska et al.
1994 [41]
Randomized
controlled trial
Children with new onset or relapsing CD
(n = 19). Ten children had widespread
disease affecting both colon and small
intestine; in three the disease was limited
to the colon and rectum, and six children
had only small bowel disease.
- 10 children treated with
a whole-protein based formula
through a nasogastric tube for 11
weeks
-9 children received high dose CS
for 11 weeks
- Similar improvements of PCDAI index, clinical
symptoms and inflammatory markers within 2 weeks
of treatment in both groups. After the end of the
follow-up period 2 months after cessation of the
treatment, PCDAI was still low in both groups
(PCDAI 11.9 ˘ 7.9 in enteral diet group and 14.3 ˘ 9.6
in CS group)
- During the routine follow-up after the trial
(0.3–2.5 years, mean 1.3 years), five of the CS group
55.5% (5/9) whereas only one from the enteral group
10% (1/10) experienced a clinical relapse.
ARC = ´0.46 (exact 95% CI ´0.8 to ´0.08).
Terrin et al. 2002
[42]
Randomized
controlled trial
Children with active CD (n = 20), aged
7–17 years, involving the terminal ileum
and different areas of the colon; no fistulae
or strictures were detected.
- Group A: CS and mesalazine
(n = 10)
- Group B: enteral nutrition group
treated with extensively
hydrolyzed formula for 8 weeks
(n = 10)
- Clinical remission was achieved in 90% (9/10) of
patients in group B but only in 50% (5/10) in
corticosteroid group (p < 0.01). ARC = 0.40 (exact 95%
CI 0.04 to 0.76). Both treatments were effective in
reducing PCDAI scores (baseline group A 32.0 ˘ 4.7,
group B 34.0 ˘ 4.3; at week 8 group A 13.0 ˘ 5.18,
group B 7.2 ˘ 3.15, p < 0.01), endoscopic scores
(baseline group A 3.7 ˘ 0.48, group B 3.8 ˘ 0.42; at
week 8 group A 2.4 ˘ 0.96, group B 1.1 ˘ 0.87,
p < 0.01) and histological scores (baseline group A
3.3 ˘ 0.67, group B 3.5 ˘ 0.52; at week 8 group A
2.5 ˘ 0.52, group B 1.3 ˘ 0.82, p < 0.05 for group A,
p < 0.01 for group B). Group B had significantly lower
post-trial PCDAI scores than the CS group (PCDAI
scores change group B 14.6 ˘ 3.6, p < 0.01, group A
24.8 ˘ 4.4, not significant))
Borrelli et al.
2006 [43]
Randomized
controlled trial Children with active naïve CD (n = 37).
- 19 children received EEN with
PF for 10 weeks
- 18 children received oral CS for
10 weeks
At week 10 the remission rate was comparable
between two groups: 15/19 (79%, 95% CI 56–92) in PF
group and 12/18 (67%, 95% CI 44–84) in CS group
(p = 0.4, not significant). ARC = 0.12 (exact 95% CI´0.16
to 0.40). The proportion of children showing mucosal
healing was significantly higher in the PF (14/19, 74%;
95% CI 51 to 89) than the CS group (6/18, 33%; 95% CI
16 to 57; p < 0.05). ARC = 0.40, (exact 95% CI 0.11 to
0.70). At week 10 both endoscopic and histologic scores
significantly decreased only in PF group.
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Table 4. Cont.
Clinical Studies Comparing Exclusive Enteral Nutrition to Corticosteroids
Author/Year Study Type Population Method Main Findings
For endoscopic score: in PF group pre-trial 12.9 ˘ 0.8,
post-trial 5.9 ˘ 0.5, p < 0.001, in CS group pre-trial
12.9 ˘ 0.9, post-trial 9.8 ˘ 1.3, not significant.
For histologic scores: in PF group ileum score pre-trial
10.4 ˘ 0.4, post-trial 3.8 ˘ 0.5, p < 0.001, in CS group
pre-trial 11.0 ˘ 04, post-trial 9.6 ˘ 0.7, not significant.
Berni Canani et
al. 2006 [44]
Retrospective
cohort study
Children with newly diagnosed CD
(n = 47), mean age 12.1 years.
Children received nutritional
therapy (NT) for 8 weeks as
- Polymeric formula (n = 12)
- Semi-elemental diet (n = 13)
- Elemental diet (n = 12)
Ten subjects received oral CS for
8 weeks.
Similar clinical remission rates were observed after
8 weeks of treatment: 86.5% (32/37) receiving NT vs.
90% (9/10) treated with CS. ARC = ´0.04 (exact 95%
CI ´0.25 to 0.18). Improvement in mucosal
inflammation occurred in 64.8% (26/37) of patients on
NT and 40% (4/10) of children on CS (p < 0.05).
Soo et al. 2013
[45]
Retrospective
cohort study
Children with newly diagnosed CD
(n = 105).
Children received either EEN
(n = 36, mean age 12.9 years) or
corticosteroids (n = 69, mean age
11.2 years) as induce
remission therapy
Remission rate similar in two groups 88.9% (32/36) in
the EEN group vs. 91.3% (63/69) in the CS group
(p = 0.73) at 3 months). ARC= ´0.02 (exact 95% CI
´0.15 to 0.10). Relapse rate (40.6% vs. 28.6%), similar
in both treatment groups (p = 0.12) over 12 months).
Luo et al. 2015
[46]
Retrospective
cohort study
Children with newly diagnosed mild to
moderate CD.
Children received either EEN
(n = 10; median age 11.6 years) or
CS (n = 18; median age 11.1 years)
for 8 weeks.
The remission rate in EEN group was significantly
higher than that in CS group (90.0% vs. 50.0%,
respectively, p < 0.05).
Grover et al. 2015
[47]
Retrospective
analysis of
records
Children with newly diagnosed CD (n = 89)
involving ileal, ileocolonic, and
colonic sites.
Children received either EEN
(n = 43; median age 13 years) or
CS (n = 46; median age 11.5 years)
as remission induction therapy
together with an early use of
thiopurines (within 6 months
from diagnosis) as maintenance
therapy. They were followed up
for at least 2 years.
Choice of EEN over CS induction was associated with
reduced linear growth failure (7% vs. 26%, p = 0.02),
CS dependency (7% vs. 43%, p = 0.002), and improved
primary sustained response to IFX (86% vs. 68%,
p = 0.02).
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More recently, novel nutritional approaches have been proposed and their efficacy has been proved
in case series and dietary intervention studies [48–51]. Table 5 summarizes the main studies on the
novel nutritional approaches for induction of remission in pediatric IBD. Among the novel approaches,
the specific carbohydrate diet (SCD) has gained attention. It restricts complex carbohydrates
and eliminates refined sugar from the diet, based on the rationale that the sugars and complex
carbohydrates are malabsorbed and could cause alterations in microbiome composition, contributing
to the intestinal inflammation of IBD. The clinical efficacy in inducing remission of symptoms and
improvement of laboratory parameters has been demonstrated by reviewing medical records and in
a prospective trial. Suskind et al. [49] reviewed medical records of children and adolescents with CD
(n = 10) aged 7–16 years, treated with the SCD for a period of 5–30 months. Symptoms of all patients
were resolved at a routine clinic visit three months after initiating the diet. Laboratory indices and fecal
calprotectin either normalized or significantly improved at the follow-up clinic visits. It must be noted
that the study was retrospective, hence the observed events (improvement of symptoms, laboratory
parameters, and fecal calprotectin) could be due to chance. Cohen et al. conducted a trial evaluating
clinical improvement and mucosal healing in children and adolescents with active CD, (mean age
13.6 years (n = 9)) after a 12–52 week trial of a SCD. The study showed at both the 12-week endpoint
and the 52-week extension period clinical improvement assessed by PCDAI. In 6/10 patients (60%)
remission was achieved by week 12. Mucosal healing (Lewis score < 135) was observed in 40% (4/10)
of patients at week 12, 80% of patients showed significant mucosal improvement at week 12 when
compared to baseline (p = 0.012) [50]. Aside from SCD, another novel dietary intervention has been
proposed and studied in a prospective randomized trial by Sigall-Boneh et al. [51]. The new approach
consists of 50% caloric intake with an exclusion diet specific for CD and 50% intake with a polymeric
formula for a period of six weeks. The authors studied children and young adults (n = 47, 34 children)
with active CD and with a mean age of 16.1 ˘ 5.6 years. The specific CD diet excludes many types of
foods, including dairy products, margarine, gluten-containing cereals, smoked products (meat and
fish), maize and potato flour, sauces, snacks, fruit juices, chocolate, coffee, and alcohol. Response and
remission was obtained in 37 (78.7%) and 33 (70.2%), patients, respectively. Remission was obtained in
70% of children and 69% of adults.
The effect of a cow’s milk protein (CMP) elimination diet on the induction and maintenance of
remission in children with ulcerative colitis (UC) has been assessed in a randomized controlled trial by
Strisciuglio et al. [52]. The authors randomized children to receive a CMP elimination diet or a free diet
associated with concomitant steroid induction and mesalazine maintenance treatment. No significant
differences were noted between the two groups in frequency of induction of remission and frequency
of relapse.
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Table 5. Novel nutritional approaches for induction of remission in pediatric IBD. SCD = Specific Carbohydrate Diet. CD = Crohn’s Disease, PEN = partial enteral
nutrition, PCDAI = Pediatric Crohn’s Disease Activity Index, IR = incidence rate.
Novel Nutritional Approaches for Induction of Remission in Pediatric IBD
Author/Year Study Type Population Method Main Findings
Gupta et al. 2013
[48]
Retrospective
cohort study
Children with active
CD (n = 23), mean
age 12.8 years.
Enteral nutrition providing
80%–90% of caloric needs,
remaining calories from normal diet
Induction of remission achieved in 65% of cases and response
in 87% of cases at a mean follow-up of 2 months.
Suskind et al.
2014 [49]
Retrospective
cohort study
Children and
adolescents with
active CD (n = 10),
age range 7–16 years
SCD as treatment of active CD
(either soon after diagnosis, or as
second line therapy if steroid
dependent or failure of mesalazine
treatment). Duration of dietary
therapy: 5–30 months.
Symptoms of all patients resolved at a routine clinic visit
3 months after initiating the diet. Laboratory indices and fecal
calprotectin either normalized or significantly improved at
the follow-up clinic visits.
Cohen et al. 2014
[50] Clinical trial
Children and
adolescents with
active CD, mean age
13.6 years (n = 9).
SCD for 101% caloric needs, for 12
and 52 weeks.
At both: 12 week and 52-week endpoint s, there was clinical
improvement assessed by PCDAI. In 6/10 patients (60%)
remission was achieved by week 12. IR = 0.60 (exact 95% CI
0.26 to 0.88). Mucosal healing (Lewis score < 135) was
observed in 40% (4/10) of patients at week 12. IR = 0.40 (exact
95% CI 0.12 to 0.74). 80% showed significant mucosal
improvement at week 12 when compared to baseline
(p = 0.012). IR = 0.80 (exact 95% CI 0.44 to 0.97).
Sigall-Boneh et al.
2014 [51] Clinical trial
Children and young
adults with active
CD n = 47 (mean age
16.1 ˘ 5.6 years,
children n = 34)
PEN with a CD exclusion diet +
50% polymeric formula for 6 weeks.
Response and remission was obtained in 37 (78.7%) and 33
(70.2%) patients respectively. IR = 0.79 (exact 95% CI 0.64 to
0.89). Remission was obtained in 70% of children and 69% of
adults. IR = 0.70 (exact 95% CI 0.55 to 0.83).
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5. Nutrition in Maintenance of Remission in Pediatric IBD
Exclusive Enteral Nutrition (EEN) is recommended as first line therapy to induce remission in
pediatric CD [53], but only few studies analyzed the effect of dietary intervention for IBD maintenance
of remission. New approaches recently proposed consider the elimination of foods thought to be
noxious, through exclusion diets, or the supplementation of anti-inflammatory substances. Some data
show that maintenance enteral nutrition (MEN) could reduce relapse rates. Table 6 summarizes
the main studies focusing on enteral nutrition in maintenance of disease remission in pediatric IBD.
In a study of Belli et al. [54], a small group of children continued intermittent EEN via nasogastric
tube (NT) for one month out of four over the course of one year, showing improvement in CD clinical
activity and growth [2]. Recently, in a retrospective study, Duncan et al. [55] analyzed 59 children with
newly diagnosed CD, showing that the remission rate at one year was significantly higher in patients
continuing MEN 60% (9/15), compared to 15% (2/13) in patients taking no treatment (p = 0.001)
and with patients taking azathioprine (p = 0.14). Referring to Partial Enteral Nutrition (PEN), data
about maintenance of remission in pediatric IBD are scarce. Evidences from adult population suggest
that this kind of treatment could reduce the risk of relapse and improve the response to biological
drugs [55–60]. A report of Wilschanski et al. [61] studied the effect of providing supplementary enteral
nutrition, in addition to normal diet, in children and adolescents affected by CD after induction of
remission with EEN. The study demonstrated fewer relapses and improvements of linear growth
in children who continued supplementary feeding respect to control group [61]. Considering new
nutritional interventions, a lacto-ovo vegetarian diet, also called a semi-vegetarian diet (SVD), has
been evaluated in a prospective study on patients affected by CD, showing a significant effect on
relapse prevention compared to an omnivorous diet (remission rate at two years 94% (15/16) for SVD
vs. 33% (2/6), p = 0.0003) [62]. Another kind of exclusion diet has been attempted by Obih et al. [63]
in a retrospective study including pediatric patients affected by CD or UC. A group of children
followed the Specific Carbohydrate Diet (SCD) for a period between three and 48 months (mean of
9.6 ˘ 0.1 months); some of the patients were treated in conjunction with medical therapy, while the
second group was treated only with standard medical therapy. The SCD group showed improvement
of clinical and inflammatory markers, but the compliance to SCD was often poor and some of the
patients who followed the SCD experienced weight loss [63].
Beyond nutritional therapy for maintenance of remission through exclusion diets, efforts are
being made to evaluate the possible efficacy of supplementation of anti-inflammatory substances.
One of the most studied is diferuloymethane, also known as curcumin. It is the most important
component of the plant Curcuma longa or turmeric, belonging to the family Zingiberaceae. This kind
of plant is typical of India, China, and Sri Lanka [64]. It is used in Indian and Chinese traditional
medicine and it appears to have many properties such as anti-inflammatory, antioxidant, anti-tumor,
antiplatelet, antibacterial, and antifungal effects [65,66]. Pathogenic mechanisms that explain all the
curcumin properties are complex and partially known, but evidences suggest that the modulation of
the NF-kB pathway has a pivotal role [67].The therapeutic use of curcumin is limited by its unfavorable
pharmacokinetics, but oral administration of the drug reaches active levels in the gastrointestinal tract,
so this natural substance could be useful for treating gut diseases [68]. Recent studies demonstrate
that curcumin may be used as an adjunctive therapy for maintenance of remission in IBD, in particular
in UC. Hanai et al. [69] evaluated the efficacy of curcumin as additional therapy for maintenance of
remission in patients between 13 and 65 years with quiescent UC and consuming mesalazine or
sulfasalazine. In this randomized, multicenter, double-blind, placebo-controlled trial, a group of
patients receiving 2 g curcumin per day for six months has been compared with a group treated
with a placebo. During the study period, relapses were lower in patients taking curcumin than in
the placebo group (2/43 (4.65%) in curcumin group vs. 8/39 (20.51%) in placebo group, p = 0.049).
Moreover, the authors noted improvements in the Clinical Activity Index (CAI) and the Endoscopic
Index (EI) (secondary pre-specified outcomes) in patients receiving curcumin (CAI, p = 0.038 and EI,
p = 0.0001) [69]. Finally, this natural anti-inflammatory agent seems to have high tolerability, without
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severe adverse effects in the pediatric population. The average intake of curcumin in countries where
it is traditionally used in the diet, such as in India, is approximately 60–100 mg of curcumin daily in
an adult individual [70]. Suskind et al. [71] enrolled 11 patients between 11 and 18 years affected by CD
or UC in a tolerability study. During the trial, the curcumin dose was gradually increased from 500 mg
twice a day to 2 g twice a day and continued for three weeks, without significant side effects [71].
Great interest has also been shown in n-3 PUFAs and their pleiotropic effects. The longer
chain n-3 PUFAs, represented by EPA, DHA, and DPA, are mainly contained in fish oil and have
numerous properties such as anti-inflammatory, anti-thrombotic, anti-arrhythmic, hypolipidemic, and
vasodilatory activity [72,73]. Their anti-inflammatory effect, especially, seems to be due to n-3’s role
in the arachidonic acid pathway and the subsequent downregulation of proinflammatory cytokine
synthesis, decreased leukocyte chemotaxis, and decreased T cell reactivity [74,75]. During the last
decades, the idea that an n-3 rich diet could have positive effects in patients affected by IBD has been
evaluated in numerous studies, particularly in the adult population, with conflicting results [76–78].
Meister et al. have studied in vitro the influence of a fish oil enriched enteral diet on intestinal tissues
taken from CD, UC, and non-IBD control patients, showing that the anti-inflammatory effect of
fish oil is significantly more marked in UC compared with CD [79]. Some evidence has shown
clinical improvement after supplementation of n-3; however the most robust evidence is from two
randomized double-blind, placebo-controlled studies on large adult populations affected by CD;
these have not demonstrated any significant effects of n-3 supplementation in relapse prevention [80],
and a recent Cochrane review has concluded that omega 3 fatty acids are probably ineffective for
maintenance of remission in CD [81]. Concerning pediatric IBD, an Italian double-blind, randomized,
placebo-controlled study showed a significant effect on reduction of relapse. The number of patients
who relapsed at 12 months was significantly lower in the Omega-3 fatty acid group (group 1) compared
to patients receiving a placebo (group 2) (relapse rate group 1 11/18 (61%), group 2 19/20 (95%);
p < 0.001 [82]. In conclusion, although Omega-3 appears to be safe, except for mild gastrointestinal
tract symptoms (diarrhea, unpleasant taste, bad breath, heartburn, and nausea), further studies are
needed to confirm the real efficacy of n-3 for IBD treatment in pediatric population. Table 4 summarizes
the main pediatric studies on nutrition in maintenance of disease remission.
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Table 6. Nutrition in maintenance of disease remission. ED = elemental diet, MEN = maintenance enteral nutrition, EEN = exclusive enteral nutrition, SCD = specific
carbohydrate diet, CRP = C-reactive protein, BMI = body mass index, 5-ASA = 5-aminosalycilates, ARC = risk change.
Nutrition in Maintenance of Disease Remission in Pediatric IBD
Author/Year Study Type Population Method Main Findings
PEN
Belli et al. 1988
[54] Clinical trial
Children and
adolescents with CD
(n = 8) aged
9.8–14.2 years
- 8 children treated with chronic
Intermittent ED for 1 month out of 4,
over the course of 1 year
- 4 children treated with conventional
medical treatment
- CD activity index and prednisone intake decreased
significantly in patients receiving ED therapy when compared
with controls on conventional medical therapy (p < 0.05).
Duncan et al.
2014 [55] Clinical trial
Children and
adolescents newly
diagnosed CD (n = 59)
aged 2.5–16.33 years
Patients newly diagnosed CD who
commenced EEN for 8 weeks, than
followed up:
- 11/59 poor response to EEN, switched
to steroids. 48/59 completed 8 weeks
with EEN and achieved remission
- 15/48 continued MEN, post EEN
completion. Duration of MEN ranged
4–14 months (mean 10.8 months)
- Remission rates at 1 year in patients continuing MEN were
60% (9/15), compared to 15% (2/13) in patients taking no
treatment (p = 0.001) and 65% (13/20) in patients taking
azathioprine (p = 0.14).
Wilschanski et al.
1996 [61]
Retrospective
cohort study
Children and
adolescents (n = 65)
aged 7–17 years
After induction of remission of CD
with EEN:
- Group 1: patients (n = 28) continued
nocturnal nasogastric supplementary
feeding combined with a normal diet
- Group 2: patients (n = 19)
stopped nocturnal supplements after
the remission
- Higher relapse rate in group 2 vs. group 2 at 6 and 12
months (At 6 months relapse rate of group 2: 78% (15/19) vs.
17.8% (5/28) of group 1, p < 0.02; at 12 months relapse rate of
group 2 78.9% (15/19) vs. group 1 42.8% (12/28), p < 0.02).
- Mean changes in height velocity was greater for group 1
(2.87 cm/year) compared to group 2 (0.4 cm/year), p =0.057.
Obih et al. 2015
[63]
Retrospective
cohort study
Children affected by IBD
(n = 26), CD (n = 20) or
UC (n = 6) aged
1.5–19 years
- Group of patients (n = 26) who
followed a SCD for more than 2 weeks
(mean duration 9.6 ˘ 10.1 months).
15/26 patients were on concurrent
medication with SCD; 11/26 were not
on IBD-related drugs
- Children with IBD (n = 10), CD (n = 7),
UC (n = 3) who did not follow SCD but
only standard medical therapy
- In SCD group PCDAI improved from 32.8 ˘ 13.2 at baseline
to 20.8 ˘ 16.6 by week 4 ˘ 2 w and 8.8 ˘ 8.5 by month 6.
- The mean Pediatric Ulcerative Colitis Index (PUCAI)
decreased from baseline 28.3 ˘ 10.3 to 20.0 + 17.3 at week
4 ˘ 2 w and to 18.3 ˘ 31.7 at month 6.
- Significant improvement of Crohn’s disease activity index,
CRP, and calprotectin in SCD group respect to control group
(p = 0.03, 0.03, and 0.03, respectively)
- lower BMI, height and weight in SCD group than in control
(p = 0.01, 0.03, and 0.009, respectively)
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Nutrition in Maintenance of Disease Remission in Pediatric IBD
Author/Year Study Type Population Method Main Findings
PEN
Curcumin
Hanai H et al.
2006 [69]
Randomized
double-blind,
placebo-controlled
trial
Adolescents and adults
with quiescent UC aged
13–65 years (n = 89)
- 43 patients received curcumin 2 g/day
plus sulfasalazine or mesalazine;
- 39 patients received placebo plus
sulfasalazine or mesalazine
- Relapse rate at 6 months of therapy was lower for curcumin
group compared to placebo group:
- 2/43 (4.65%) in curcumin group vs. 8/39 (20.51%) in placebo
group, p = 0.049. ARC = ´0.16 (exact 95% CI ´0.30 to ´0.02).
- Curcumin improved both clinical activity index (CAI,
p = 0.038) and endoscopic index (EI, p = 0.0001).
- High tolerability and no serious side effect associated
to curcumin
Suskind et al.
2013 [71] Clinical trial
Children and
adolescents (n = 11) aged
11–18 years affective by
CD (n = 6) or UC (n = 5).
All patients, in addition to their
standard IBD therapy, received
increasing doses of curcumin, up to 2 g
twice daily for 3 weeks
- High tolerability of curcumin without side effects except for
increase in gassiness which was consistently reported in
two patients. Three patients had lowering of
PUCAI/PCDAI scores.
- No patients had IBD relapse or worsening of symptoms.
n-3 PUFAs
Romano et al.
2005 [82]
Double-blind,
randomized,
placebo-controlled
study
Children and
adolescents affected by
CD (n = 38) in remission,
aged 5–16 years and
treated for 12 months.
- Group 1 (n = 18): patients treated with
5-ASA (50 mg/kg/day) and omega-3
fatty acids for 12 months.
- Group 2 (n = 20): patients treated with
5-ASA (50 mg/kg/day) plus placebo
(olive oil in capsules) for 12 months.
Number of patients who relapsed at 12 months was
significantly lower in Omega-3 fatty acid group than in
patients receiving placebo (relapse rate group 1 11/18 (61%),
group 2 19/20 (95%); p < 0.001). ARC ´0.34 (exact 95% CI
´0.58 to ´0.09).
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6. Health Benefits of Nutritional Therapy in Pediatric IBD
With respect to adult forms, pediatric IBD have specific features, not only for severity and
extension, but also because the disease involves growing individuals, with possible irreversible
consequences in adult life. Weight loss and failure to thrive, delayed puberty, and low bone mineral
density are frequent signs in children affected by IBD, in particular in CD, because of malabsorption
and malnutrition. The etiology of poor nutritional status in children affected by IBD is complex and
involves reduced dietary intake, increased gastrointestinal nutrient losses, increased energy requests
due to inflammation, and altered metabolism [83,84]. Moreover, the linear growth and nutritional
status of children affected by IBD are also compromised by immunosuppressant drugs, especially
corticosteroids, used for the treatment of the disease [85]. All these reasons justify the particular
importance of nutritional therapy in pediatric IBD. EEN is at least as efficacious as corticosteroids in
inducing remission in pediatric CD, but it has minimal side effects and several advantages in terms
of mucosal healing, restoration of nutritional status, bone health, and liner growth in children [53].
Multiple studies demonstrate that, with respect to conventional immunosuppressant drugs, nutritional
therapy improves weight gain, height velocity, body composition, and insulin-like growth factor (IGF)-1
and IGF binding protein 3 (IGFBP-3) [18,54,61,86–90]. Table 5 illustrates the main studies on the health
benefits of nutritional therapy in pediatric IBD. Berni Canani et al. [44], in a retrospective study on
47 children with active CD, compared the effect of EEN versus corticosteroid therapy. Children treated
with EEN for eight weeks showed higher serum iron and albumin levels, and more pronounced linear
growth than group treated with corticosteroids [44]. Moreover, bone health seems to benefit from
nutritional therapy too. The pathogenesis of bone loss in pediatric IBD is complex: malnutrition,
compromised linear growth, lean mass deficit, delayed puberty, menstrual irregularity, reduced
physical activity, persistent inflammation, and prolonged use of corticoids are the major factors
responsible [91–93]. Although the direct effect of EEN in increasing bone mineral density (BMD) has
been poorly studied, Whitten et al. demonstrated that the normalization of bone turnover markers
in children was affected by CD after eight weeks of treatment with EEN [6]. In addition, in the latest
clinical guidelines about skeletal health issued by ESPGHAN and NASPGHAN, the authors affirm the
benefits of enteral nutrition. In terms of linear growth and lean mass, EEN or supplemental enteral
nutrition could induce improvement of bone health, and they recommend these tactics not only during
the acute phase, but also during remission phases of IBD, particularly in children and adolescents with
delayed linear growth [7]. Table 7 shows the main studies on the health benefits of nutritional therapy
in pediatric IBD.
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Table 7. Health benefits of nutritional therapy in pediatric IBD. ED = elemental diet, REE = resting energy expenditure, IGF-1 = insulin like growth factor 1,
IGFBP-3 = insulin like growth factor binding protein, EEN = exclusive enteral nutrition, corticosteroids = CS.
Health Benefits of Nutritional Therapy in Pediatric IBD
Author/Year Study Type Population Method Main Findings
Azcue et al.
1997 [83] Clinical trial
Children and adolescents
affected by CD (n = 24);
malnourished adolescents with
anorexia nervosa (n = 19);
healthy control subjects (n = 22)
- Group of patients (n = 12) treated
with nocturnal enteral nutrition via
nasogastric tube for 5–6 weeks, then
1 night a week for 2 months
- Group of patients (n = 12) treated
with prednisolone
- control group (n = 22),
healthy subjects
- group of malnourished
adolescents with anorexia nervosa
(n = 19)
- All body compartments and REE increased significantly in
enteral nutrition group compared to patients treated with
corticosteroids. In enteral nutrition group REE (kcal/day)
from 1153 ˘ 283 at baseline to 1415 ˘ 535 at 1 month
post-treatment; in prednisolone group REE at baseline
1380 ˘ 308 to 1432 ˘ 265 at one month post-treatment.
For lean body mass (LBM % weight) in enteral nutrition
group 86.6 ˘ 8.9 at baseline to 88.8 + 9.9 at one month
post-treatment, in prednisolone group 87.5 ˘ 9.4 at baseline to
79.1 ˘ 9.4 at one month post-treatment.
- Significant height increase in enteral nutrition group
compared with prednisolone group (p < 0.01).
Beattie et al.
1998 [86] Clinical trial
Children and adolescents
affected by CD (n = 23)
- Study A: 14 patients treated with
EEN for 8 weeks, then gradual
reduction of nutritional support
over 2 months
- Study B: 9 patients treated with
intestinal resection
Study A
- Significant weight gain for all patients treated with EEN after
8 and 16 weeks, compared to pre-treatment values (weight
SDS at baseline= -0.9 (´1.3 to ´0.5), weight SDS at
week 8 = ´0.5 (´0.9 to 0), at 16 weeks weight
SDS = ´0.6 (´1.1 to 0) (p < 0.05)
- Significant increase of median IGF-1 and IGFBP-3 at 2, 8,
and 16 weeks in EEN group compared to pre-treatment
values (p < 0.01)
Study B
- No significant changes in auxological data, IGF-1 and
IGFBP-3 in patients who had surgical resection compared to
pre-treatment values
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Wilschanski
et al. 1996
[61]
Retrospective
cohort study
Children and adolescents
(n = 65) aged 7–17 years
After induction of remission of CD
with EEN:
- Group 1: patients (n = 28)
continued nocturnal nasogastric
supplementary feeding combined
with a normal diet
- Group 2: patients (n = 19)
stopped nocturnal supplements
after the remission
- Mean changes in height velocity was greater for group 1
(2.87 cm/year) compared to group 2 (0.4 cm/year), p = 0.057.
Belli et al.
1988 [54] Clinical trial
Children and adolescents with
CD (n = 8) aged 9.8–14.2 years
- 8 children treated with chronic
intermittent enteral ED for 1 month
out of 4, over the course of 1 year
- 4 children treated with
conventional medical treatment
- Significant height and weight gains in the ED group vs.
controls. Weight gain for ED group 6.9 ˘ 1.5 kg;
209.8% ˘ 41.9%; weight gain for control group ´0.9 + 1.6 kg;
´9.8% ˘ 52.6% (p < 0.01). Height changes in ED group
7.0 + 0.8 cm; 126.0% ˘ 11.8% of ideal predicted. Height
change in control group 1.7 + 0.8 cm; 28.7%˘ 13.1% (p < 0.01).
Berni Canani
et al. 2006
[44]
Retrospective
study
Children and adolescents
affected by active CD (n = 47)
Children received nutritional
therapy (NT) for 8 weeks as
- Polymeric formula (n = 12)
- Semi-elemental diet (n = 13)
- Elemental diet (n = 12)
Ten subjects received oral CS for
8 weeks.
- Significant improvement of serum albumin and iron levels
in NT compared to CS group. In NT group elemental:
albumin at baseline 13.14 ˘ 0.47 to 3.98 ˘ 0.36 at 8 weeks,
p < 0.001; NT group semi-elemental: albumin at baseline
3.13 + 0.40 to 3.88 + 0.26 at 8 weeks, p < 0.001; NT group
polymeric: albumin at baseline 3.09 + 0.39 to 3.86 + 0.38 at
8 weeks, p < 0.001)). In CS group: albumin at baseline
3.37 ˘ 0.24 to 3.40 ˘ 0.22 after 8 weeks, p = 0.28).
In NT group elemental: iron at baseline 31.25 ˘ 20.4 to
72.17 ˘ 20.4 at 8 weeks, p = 0.001; NT group semi-elemental:
iron at baseline 29.46 + 23.7 to 66.69 + 19.8 at 8 weeks,
p = 0.002; NT group polymeric: iron at baseline 32.58 + 24.0 to
69.25 + 29.6 at 8 weeks, p = 0.004)). In CS group: iron at
baseline 20.80 ˘ 15.5 to 35.80 ˘ 16.0 after 8 weeks, p = 0.01).
Linear growth recovery was superior in nutritional group
compared to CS group (p < 0.05).
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Motil et al.
1982 [87] Clinical trial Adolescents affected by CD
- 6 patients affected by CD received
nutritional supplements for
7 months
- 5 healthy control subjects
Increase of linear and ponderal growth velocities in patients
treated with nutritional support (Height gain cm/month
pre-supplements 0.10 ˘ 0.08, post-supplements 0.50 + 0.16;
weight gain kg/month pre-supplements 0.21 ˘ 0.09,
post-supplements 1.22 ˘ 0.25). Achievement of weight and
height gain similar to control group levels after the 7 months
treatment with nutritional supplements (height gain
cm/month 0.38 ˘ 0.12, weight gain kg/month 0.40 + 0.17).
O’Morain et
al. 1983 [88] Clinical trial
Children and adolescents
affected by CD (n = 15) aged
6–20 years
14 patients received ED as the main
energy source for 4 weeks;
1 received corticosteroids.
Improvement of nutritional status, weight, and height gain in
children receiving ED.
Whitten et al.
2010 [94] Clinical trial
Children newly diagnosed CD
(n = 23) compared to a healthy
control group (n = 20)
Children newly diagnosed with CD
received 8 weeks EEN for induction
of remission
Normalization of serum markers of bone turnover after EEN
therapy. CTX levels at diagnosis 2.967 ˘ 0.881 ng/mL and
after EEN 2.260 ˘ 0.547 ng/mL, p = 0.002. BAP levels at
diagnosis 51.24 ˘ 31.31 microg/L and after EEN
64.82 ˘ 30.51 microg/L, p = 0.02.
Polk et al.
1992 [89] Clinical trial
Adolescents affected by CD
(n = 6)
All patients received enteral
nutrition via nasogastric tube
during night 1 out of 4 months for
1 year. Then the patients received
a 2-week exclusion diet and
a 2-week low-residue diet for
2 months, before re-starting
a normal diet.
Significant increase of weight, height, IGF-1, and albumin;
decrease of steroid use and disease activity compared to
pretreatment values
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7. Strengths and Limitations
The main strength of the present systematic review is the rigorous methodological assessment
and analysis of the literature using pre-specified criteria. The methods we used helped to reduce the
risk of bias (thorough literature research performed by two researchers independently and duplicate
data abstraction). Nevertheless, some limitations should be pointed out. In the first instance, the
methodological quality of included trials was not high and some trials had small sample sizes.
Moreover, a significant limitation lies in the lack of standardization of outcome measures, clinical
heterogeneity of subjects enrolled, variation in the length of follow-up and in the duration of
interventions, and the use of concomitant medications.
8. Conclusions
Nutrition has a significant role in pediatric IBD. With regards to etiology, the available pediatric
data suggest that dietary patterns characterized by consumption of meats, fatty foods, desserts, and
a high sugar intake are associated with an increased risk of disease. Likely protective factors are
represented by consumption of vegetables, fruits, fish, olive oil, and wholemeal bread. Large scale
randomized controlled clinical trials are needed to confirm these data.
For treatment of disease, EEN is the only nutritional approach with robust evidence of
effectiveness in induction of remission; PEN is known to be advantageous in reducing relapse rates.
Besides the known elemental, semi-elemental, and polymeric formulas, the scientific community
is currently looking into modifying dietary habits to maintain disease remission mainly through
exclusion diets: the Specific Carbohydrate Diet and the Crohn’s Disease exclusion diet are now in the
spotlight. Nevertheless, the poor compliance to nutritional intervention and the risk of nutritional
deficits when exclusion diets are too strict are factors that have to be considered when these kinds
of treatments are proposed. Despite the promising results of the novel nutritional approaches, the
available data are not strong enough to recommend these interventions in clinical practice and new
large controlled studies are needed, especially in pediatric population, to confirm these data.
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